Filipa Aragão
Filipa Aragão has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
Belén de la Fuente
Hospital Universitario de Cabueñes, Gijón, Spain
2 shared publicationsBernardino Roca
Hospital General Univrsitari, Castellón, Spain
2 shared publicationsElisa Martínez
Complejo Hospitalario Universitario, Albacete, Spain
2 shared publicationsElisabeth Deig
Hospital General, Granollers, Spain
2 shared publicationsHelena Diaz-Cuervo
Gilead Sciences, Medical Affairs, Stockley Park MAOR, Madrid, Spain
2 shared publicationsJoaquim Peraire
Hospital Universitari Joan XXIII, Tarragona, Spain
2 shared publications
Latest Publications
- Open Access
- 17 September 2026
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 6 (1) , e281
Cost benefits of implementing rapid PCR-based screening for carbapenemase-producing Enterobacteriaceae in high-risk hospitalized patients in Spain
Objective: European carbapenemase-producing Enterobacteriaceae (CPE) screening guidelines recommend preventive contact precautions (PrevCP; contact precautions before screening test results) and rapid, sensitive screening for high-risk hospitalized patients (HRHP) upon hospital admission. This analysis assessed the cost impact of adopting on-demand molecular PCR CPE screening in HRHP versus current standard of care (SoC) in Spain. Design: Decision-tree model. Setting: Spain. Patients: HRHP defined as those admitted to high-risk units or with a history of previous admission(s) with detected CPE carriage. Methods: SoC was defined as a weighted average of the strategies “PrevCP & Screen” by culture, “No PrevCP & Screen” by culture, and “No PrevCP & No Screen.” A decision-tree model was developed to quantify the cost of replacing current SoC with PrevCP+rapid PCR screening for all HRHP at admission. Additional screening strategies versus SoC were also analyzed. A time horizon of 60 days was considered, and the payer perspective adopted. Inputs were from the literature, co-authors’ own data, and expert opinion. Costs per hospital stay are reported per HRHP, in Euros 2024. Due to lack of robust evidence on nosocomial transmission costs, such costs were excluded from the analysis. Extensive sensitivity analysis was performed. Results: The average total cost/HRHP with SoC was 11,949€. Implementing screening for all HRHP with culture increased the average total cost/HRHP by 502€. However, implementing screening for all HRHP with PrevCP+rapid PCR, when compared with SoC, generated savings of 1,092€/HRHP. Conclusions: Implementation of PrevCP+rapid molecular PCR screening for CPE in HRHP leads to cost savings in Spain.
- 17 September 2026
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 6 (1) , e281
Open AccessCost benefits of implementing rapid PCR-based screening for carbapenemase-producing Enterobacteriaceae in high-risk hospitalized patients in Spain
Objective: European carbapenemase-producing Enterobacteriaceae (CPE) screening guidelines recommend preventive contact precautions (PrevCP; contact precautions before screening test results) and rapid, sensitive screening for high-risk hospitalized patients (HRHP) upon hospital admission. This analysis assessed the cost impact of adopting on-demand molecular PCR CPE screening in HRHP versus current standard of care (SoC) in Spain. Design: Decision-tree model. Setting: Spain. Patients: HRHP defined as those admitted to high-risk units or with a history of previous admission(s) with detected CPE carriage. Methods: SoC was defined as a weighted average of the strategies “PrevCP & Screen” by culture, “No PrevCP & Screen” by culture, and “No PrevCP & No Screen.” A decision-tree model was developed to quantify the cost of replacing current SoC with PrevCP+rapid PCR screening for all HRHP at admission. Additional screening strategies versus SoC were also analyzed. A time horizon of 60 days was considered, and the payer perspective adopted. Inputs were from the literature, co-authors’ own data, and expert opinion. Costs per hospital stay are reported per HRHP, in Euros 2024. Due to lack of robust evidence on nosocomial transmission costs, such costs were excluded from the analysis. Extensive sensitivity analysis was performed. Results: The average total cost/HRHP with SoC was 11,949€. Implementing screening for all HRHP with culture increased the average total cost/HRHP by 502€. However, implementing screening for all HRHP with PrevCP+rapid PCR, when compared with SoC, generated savings of 1,092€/HRHP. Conclusions: Implementation of PrevCP+rapid molecular PCR screening for CPE in HRHP leads to cost savings in Spain.
- Open Access
- 14 August 2026
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 29 (1) , 2150-2160
Impact on health outcomes of treating all eligible large B-cell lymphoma patients with axicabtagene ciloleucel in Portugal – A modeling approach
Cancer is the main cause of premature death in Portugal, and as such, reducing preventable and premature cancer deaths is one of the main public health priorities in the coming years1. In 2020, non...
- 14 August 2026
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 29 (1) , 2150-2160
Open AccessImpact on health outcomes of treating all eligible large B-cell lymphoma patients with axicabtagene ciloleucel in Portugal – A modeling approach
Cancer is the main cause of premature death in Portugal, and as such, reducing preventable and premature cancer deaths is one of the main public health priorities in the coming years1. In 2020, non...
- Open Access
- 16 July 2026
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 29 (1) , 1998-2009
Impact of screening all high-risk patients at hospital admission for methicillin-resistant Staphylococcus aureus in Spain: a cost-consequence analysis
Methicillin-resistant Staphylococcus aureus (MRSA) is a challenge for health systems because it is relatively common, easily transmitted, and can cause infections that are difficult to manage. Appr...
- 16 July 2026
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 29 (1) , 1998-2009
Open AccessImpact of screening all high-risk patients at hospital admission for methicillin-resistant Staphylococcus aureus in Spain: a cost-consequence analysis
Methicillin-resistant Staphylococcus aureus (MRSA) is a challenge for health systems because it is relatively common, easily transmitted, and can cause infections that are difficult to manage. Appr...
- Open Access
- 21 March 2022
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 25 (1) , 309-320
Cost-effectiveness of andexanet alfa versus four-factor prothrombin complex concentrate for the treatment of oral factor Xa inhibitor-related intracranial hemorrhage in the US
To conduct a cost-effectiveness analysis (CEA) on the use of andexanet alfa for the treatment of factor Xa inhibitor-related intracranial hemorrhage (ICH) from the US third-party payer and societal...
- 21 March 2022
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 25 (1) , 309-320
Open AccessCost-effectiveness of andexanet alfa versus four-factor prothrombin complex concentrate for the treatment of oral factor Xa inhibitor-related intracranial hemorrhage in the US
To conduct a cost-effectiveness analysis (CEA) on the use of andexanet alfa for the treatment of factor Xa inhibitor-related intracranial hemorrhage (ICH) from the US third-party payer and societal...
- 4 May 2021
- Published by Taylor & Francis in HIV Research & Clinical Practice
- Vol. 22 (3) , 78-85
eGFR-EPI changes among HIV patients who switch from F/TDF to F/TAF while maintaining the same third agent in the Spanish VACH cohort
Background: Evidence from clinical practice on the effects of switching from emtricitabine/tenofovir disoproxil fumarate (F/TDF) to emtricitabine/tenofovir alafenamide (F/TAF)-based triple-therapy (TT) regimens on renal parameters is limited. Objective: This retrospective analysis evaluated the effects on renal function of switching from F/TDF to F/TAF-based TT regimens with no change in third agent among people living with HIV (PLWH). Methods: Data were from a multicenter Spanish PLWH cohort. Patients with a baseline estimated glomerular filtration rate (eGFR-EPI) measurement, >= 1 follow-up measurement, >= 30 days treatment with F/TAF, and who switched from F/TDF to F/TAF with no change in third agent were included. Multivariate mixed linear models were used to evaluate change from baseline over time in eGFR-EPI. eGFR-EPI changes before and after switch were analyzed in a matched patient subgroup. Results: Overall, 340 patients were included. Mean (95% CI) eGFR-EPI in patients with baseline eGFR-EPI <90 ml/min/1.73m(2) (n = 125) was 79.6 (78.0; 81.2) ml/min/1.73m(2) at baseline and 81.3 (79.9; 82.7) ml/min/1.73m(2) at 12 months after switch. In the patient-matched subgroup (n = 175), median annual eGFR-EPI declined -4.24 ml/min/1.73m(2) while on F/TDF and increased +0.93 ml/min/1.73m(2) after switch to F/TAF (P < 0.0001). In patients with baseline eGFR-EPI <90 ml/min/1.73m(2), median annual eGFR-EPI increased +4.19 mL/min/1.73m(2) after switch (P < 0.0001). Conclusion: Switching from F/TDF to F/TAF-based TT regimens while maintaining the same third agent numerically improved eGFR-EPI in PLWH with baseline eGFR-EPI <90 mL/min/1.73m(2). eGFR-EPI improved significantly when comparing progression while on F/TDF vs progression after switch, confirming beneficial renal effects of switching to F/TAF in a clinical practice setting.
- 4 May 2021
- Published by Taylor & Francis in HIV Research & Clinical Practice
- Vol. 22 (3) , 78-85
eGFR-EPI changes among HIV patients who switch from F/TDF to F/TAF while maintaining the same third agent in the Spanish VACH cohort
Background: Evidence from clinical practice on the effects of switching from emtricitabine/tenofovir disoproxil fumarate (F/TDF) to emtricitabine/tenofovir alafenamide (F/TAF)-based triple-therapy (TT) regimens on renal parameters is limited. Objective: This retrospective analysis evaluated the effects on renal function of switching from F/TDF to F/TAF-based TT regimens with no change in third agent among people living with HIV (PLWH). Methods: Data were from a multicenter Spanish PLWH cohort. Patients with a baseline estimated glomerular filtration rate (eGFR-EPI) measurement, >= 1 follow-up measurement, >= 30 days treatment with F/TAF, and who switched from F/TDF to F/TAF with no change in third agent were included. Multivariate mixed linear models were used to evaluate change from baseline over time in eGFR-EPI. eGFR-EPI changes before and after switch were analyzed in a matched patient subgroup. Results: Overall, 340 patients were included. Mean (95% CI) eGFR-EPI in patients with baseline eGFR-EPI <90 ml/min/1.73m(2) (n = 125) was 79.6 (78.0; 81.2) ml/min/1.73m(2) at baseline and 81.3 (79.9; 82.7) ml/min/1.73m(2) at 12 months after switch. In the patient-matched subgroup (n = 175), median annual eGFR-EPI declined -4.24 ml/min/1.73m(2) while on F/TDF and increased +0.93 ml/min/1.73m(2) after switch to F/TAF (P < 0.0001). In patients with baseline eGFR-EPI <90 ml/min/1.73m(2), median annual eGFR-EPI increased +4.19 mL/min/1.73m(2) after switch (P < 0.0001). Conclusion: Switching from F/TDF to F/TAF-based TT regimens while maintaining the same third agent numerically improved eGFR-EPI in PLWH with baseline eGFR-EPI <90 mL/min/1.73m(2). eGFR-EPI improved significantly when comparing progression while on F/TDF vs progression after switch, confirming beneficial renal effects of switching to F/TAF in a clinical practice setting.
- Open Access
- 8 April 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (4) , e0249515
Real world effectiveness of standard of care triple therapy versus two-drug combinations for treatment of people living with HIV
Background: Since 1996, the standard of care (SOC) therapy for HIV treatment has consisted of a backbone of two nucleoside analogue reverse transcriptase inhibitors (NRTI) paired with a third agent. Use of two-drug combinations (2DC) has been considered for selected patients to avoid toxicities associated with the use of NRTIs. This study aimed to compare the real-world outcomes of integrase strand transfer inhibitor (INSTI)-containing triple therapy (TT) to dolutegravir- (DTG) and/or boosted protease inhibitor (bPI)-based 2DC in a large Spanish cohort of HIV patients. Methods: A retrospective analysis was performed using data from the VACH cohort, a prospective multicentre Spanish cohort of adult HIV patients. All treatment experienced patients initiating a TT of an INSTI combined with two NRTIs or a 2DC-containing DTG and/or a bPI between 01/01/2012 and 01/06/2017 were included. The unit of analysis was patient-regimens. The overall sample analysis was complemented with two sub-analyses. The first sub-analysis focused on patients treated with a backbone plus DTG compared to those treated with DTG+ one other antiretroviral. The second sub-analysis focused on patients with HIV RNA<50 copies/mL at baseline, irrespective of the regimen used. The following endpoints were assessed: time to discontinuation for any reason, time to switch due to virologic failure, and time to switch due to toxicity (reasons for discontinuation according to clinician report in the database). Time-to-event analyses were conducted using Kaplan–Meier survival curves and Cox regression models. Results: Overall 7,481 patients were included in the analysis, contributing to 9,243 patient-regimens. Patient characteristics at baseline differed among groups, with the 2DC group being significantly older and having a higher proportion of women, a longer time on ART and a higher number of previous virologic failures. Median (95% Confidence Interval [C.I.]) time to switch was 2.5 years (2.3, 2.7) in 2DC group versus 2.9 years (2.7, 3.0) in TT. Adjusted hazard ratios (95% C.I.) for discontinuation due to any reason, virologic failure and toxicity in the 2DC vs TT group were 1.29 (1.15; 1.44), 2.06 (1.54; 2.77) and 1.18 (0.94; 1.48), respectively. Results were consistent in the two sub-analyses. Conclusion: In this analysis, time to discontinuation and probability of remaining free of virologic failure were significantly higher in patients on INSTI-based TT compared to DTG- and/or bPI-containing 2DC, with no differences in toxicity.
- 8 April 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (4) , e0249515
Open AccessReal world effectiveness of standard of care triple therapy versus two-drug combinations for treatment of people living with HIV
Background: Since 1996, the standard of care (SOC) therapy for HIV treatment has consisted of a backbone of two nucleoside analogue reverse transcriptase inhibitors (NRTI) paired with a third agent. Use of two-drug combinations (2DC) has been considered for selected patients to avoid toxicities associated with the use of NRTIs. This study aimed to compare the real-world outcomes of integrase strand transfer inhibitor (INSTI)-containing triple therapy (TT) to dolutegravir- (DTG) and/or boosted protease inhibitor (bPI)-based 2DC in a large Spanish cohort of HIV patients. Methods: A retrospective analysis was performed using data from the VACH cohort, a prospective multicentre Spanish cohort of adult HIV patients. All treatment experienced patients initiating a TT of an INSTI combined with two NRTIs or a 2DC-containing DTG and/or a bPI between 01/01/2012 and 01/06/2017 were included. The unit of analysis was patient-regimens. The overall sample analysis was complemented with two sub-analyses. The first sub-analysis focused on patients treated with a backbone plus DTG compared to those treated with DTG+ one other antiretroviral. The second sub-analysis focused on patients with HIV RNA<50 copies/mL at baseline, irrespective of the regimen used. The following endpoints were assessed: time to discontinuation for any reason, time to switch due to virologic failure, and time to switch due to toxicity (reasons for discontinuation according to clinician report in the database). Time-to-event analyses were conducted using Kaplan–Meier survival curves and Cox regression models. Results: Overall 7,481 patients were included in the analysis, contributing to 9,243 patient-regimens. Patient characteristics at baseline differed among groups, with the 2DC group being significantly older and having a higher proportion of women, a longer time on ART and a higher number of previous virologic failures. Median (95% Confidence Interval [C.I.]) time to switch was 2.5 years (2.3, 2.7) in 2DC group versus 2.9 years (2.7, 3.0) in TT. Adjusted hazard ratios (95% C.I.) for discontinuation due to any reason, virologic failure and toxicity in the 2DC vs TT group were 1.29 (1.15; 1.44), 2.06 (1.54; 2.77) and 1.18 (0.94; 1.48), respectively. Results were consistent in the two sub-analyses. Conclusion: In this analysis, time to discontinuation and probability of remaining free of virologic failure were significantly higher in patients on INSTI-based TT compared to DTG- and/or bPI-containing 2DC, with no differences in toxicity.
- Open Access
- 16 March 2013
- Published by Springer Nature in BMC Cancer
- Vol. 13 (1) , 122
Time-dependent endpoints as predictors of overall survival in multiple myeloma
Supporting health care sector decisions using time-dependent endpoints (TDEs) such as time to progression (TTP), progression-free survival (PFS), and event-free survival (EFS) remains controversial. This study estimated the quantitative relationship between median TDE and median overall survival (OS) in multiple myeloma (MM) patients.
- 16 March 2013
- Published by Springer Nature in BMC Cancer
- Vol. 13 (1) , 122
Open AccessTime-dependent endpoints as predictors of overall survival in multiple myeloma
Supporting health care sector decisions using time-dependent endpoints (TDEs) such as time to progression (TTP), progression-free survival (PFS), and event-free survival (EFS) remains controversial. This study estimated the quantitative relationship between median TDE and median overall survival (OS) in multiple myeloma (MM) patients.
- Open Access
- 17 September 2012
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (9) , e44774
Cost-Effectiveness of the Third-Agent Class in Treatment-Naive Human Immunodeficiency Virus-Infected Patients in Portugal
Current Portuguese HIV treatment guidelines recommend initiating antiretroviral therapy with a regimen composed of two Nucleoside Reverse Transcriptase Inhibitors plus one Non-nucleoside Reverse Transcriptase Inhibitor (2NRTI+NNRTI) or two Nucleoside Reverse Transcriptase Inhibitors plus one boosted protease inhibitor (2NRTI+PI/r). Given the lower daily cost of NNRTI as the third agent when compared to the average daily costs of PI/r, it is relevant to estimate the long term impact of each treatment option in the Portuguese context. We developed a microsimulation discrete events model for cost-effectiveness analysis of HIV treatment, simulating individual paths from ART initiation to death. Four driving forces determine the course of events: CD4+ cell count, viral load, resistance and adherence. Distributions of time to event are conditional to individuals’ characteristics and past history. Time to event was modeled using parametric survival analysis using Stata 11®. Disease progression was structured according to therapy lines and the model was parameterized with cohort Portuguese observational data. All resources were valued at 2009 prices. The National Health Service’s perspective was assumed considering a lifetime horizon and a 5% annual discount rate. In this analysis, initiating therapy with two Nucleoside Reverse Transcriptase Inhibitors plus one Non-nucleoside Reverse Transcriptase Inhibitor reduces the average number of switches by 17%, saves 19.573€ per individual and increases life expectancy by 1.7 months showing to be a dominant strategy in 57% of the simulations when compared to two Nucleoside Reverse Transcriptase Inhibitors plus one boosted protease inhibitor. This study suggests that, when clinically valid, initiating therapy with two Nucleoside Reverse Transcriptase Inhibitors plus one Non-nucleoside Reverse Transcriptase Inhibitor is a cost-saving strategy and equally effective when compared to two Nucleoside Reverse Transcriptase Inhibitors plus one boosted protease inhibitor as the first regimen.
- 17 September 2012
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (9) , e44774
Open AccessCost-Effectiveness of the Third-Agent Class in Treatment-Naive Human Immunodeficiency Virus-Infected Patients in Portugal
Current Portuguese HIV treatment guidelines recommend initiating antiretroviral therapy with a regimen composed of two Nucleoside Reverse Transcriptase Inhibitors plus one Non-nucleoside Reverse Transcriptase Inhibitor (2NRTI+NNRTI) or two Nucleoside Reverse Transcriptase Inhibitors plus one boosted protease inhibitor (2NRTI+PI/r). Given the lower daily cost of NNRTI as the third agent when compared to the average daily costs of PI/r, it is relevant to estimate the long term impact of each treatment option in the Portuguese context. We developed a microsimulation discrete events model for cost-effectiveness analysis of HIV treatment, simulating individual paths from ART initiation to death. Four driving forces determine the course of events: CD4+ cell count, viral load, resistance and adherence. Distributions of time to event are conditional to individuals’ characteristics and past history. Time to event was modeled using parametric survival analysis using Stata 11®. Disease progression was structured according to therapy lines and the model was parameterized with cohort Portuguese observational data. All resources were valued at 2009 prices. The National Health Service’s perspective was assumed considering a lifetime horizon and a 5% annual discount rate. In this analysis, initiating therapy with two Nucleoside Reverse Transcriptase Inhibitors plus one Non-nucleoside Reverse Transcriptase Inhibitor reduces the average number of switches by 17%, saves 19.573€ per individual and increases life expectancy by 1.7 months showing to be a dominant strategy in 57% of the simulations when compared to two Nucleoside Reverse Transcriptase Inhibitors plus one boosted protease inhibitor. This study suggests that, when clinically valid, initiating therapy with two Nucleoside Reverse Transcriptase Inhibitors plus one Non-nucleoside Reverse Transcriptase Inhibitor is a cost-saving strategy and equally effective when compared to two Nucleoside Reverse Transcriptase Inhibitors plus one boosted protease inhibitor as the first regimen.